Business Context and Reporting Period
Company: Arrowhead Research Corporation (f/k/a Arrowhead Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Model: A development-stage nanotechnology company utilizing a portfolio approach with five majority-owned subsidiaries (Insert Therapeutics, Calando Pharmaceuticals, Unidym, Tego BioSciences, and Aonex Technologies) to commercialize technologies in life sciences, electronics, and energy. The company also funds sponsored research at universities (e.g., Caltech, Stanford, Duke) to secure exclusive licensing rights.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2007 | Nine Months Ended June 30, 2007 |
|---|---|---|
| Revenue | $622,599 | $629,994 |
| Cost of Goods Sold | $347,601 | $347,601 |
| Gross Profit | $274,998 | $282,393 |
| Operating Expenses | $13,672,290 | $26,589,864 |
| Operating Loss | $(13,397,292) | $(26,307,471) |
| Net Loss | $(12,477,548) | $(22,358,528) |
| Loss Per Share (Basic & Diluted) | $(0.34) | $(0.64) |
| Cash and Cash Equivalents (Balance Sheet) | $3,421,278 (as of June 30, 2007) | |
| Marketable Securities | $27,372,602 (US Treasury Bills) | |
| Total Current Assets | $32,105,698 | |
| Total Current Liabilities | $2,940,122 | |
| Accumulated Deficit | $(50,834,846) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased to $622,599 for the quarter ended June 30, 2007, compared to $246,229 in the same period in 2006. This increase is driven by $409,000 in funded research and $207,000 in carbon nanotube sales from the Unidym subsidiary.
- Significant Increase in Loss: The net loss for the quarter widened to $12.5 million from $4.1 million in the prior year. The nine-month loss increased to $22.4 million from $12.6 million.
- Non-Cash Charges: A material non-cash charge of approximately $5.4 million was recorded for "Purchased In-Process Research and Development" (IPR&D) related to the April 2007 merger of Unidym with Carbon Nanotechnologies, Inc. (CNI).
- Operating Expenses: Total operating expenses rose to $13.7 million for the quarter (from $4.8 million prior year) due to the CNI merger charge, increased R&D for clinical trial preparations (Insert and Calando), and expanded operations at Unidym.
- Liquidity: Cash and cash equivalents decreased from $28.0 million at September 30, 2006, to $3.4 million at June 30, 2007, though total liquid assets (including marketable securities) remained robust at approximately $30.8 million.
Guidance, Outlook, and Risks
- Capital Resources: The company raised approximately $15.2 million in net proceeds from a private placement in May 2007. Management believes current cash on hand is sufficient to fund operations through the second quarter of Fiscal 2008.
- Subsidiary Milestones:
- Insert Therapeutics: Phase I clinical trials for IT-101 (anti-cancer) are ongoing; final data expected late 2007. Phase II trials targeted for late 2007 or early 2008.
- Calando Pharmaceuticals: Preparing to file an Investigational New Drug (IND) application in September 2007, with Phase I trials expected by the end of 2007. Arrowhead has committed up to $7 million in additional capital contingent on milestones.
- Unidym: Following the CNI merger, Unidym is the first subsidiary with manufacturing and sales capabilities. It is developing transparent conductive films for electronics.
- Risks and Contingencies:
- Integration Risk: Risks associated with integrating Unidym's California and Texas operations following the CNI merger.
- Liability Exposure: Potential liability for damages arising from CNI's pre-merger operations despite the reverse triangular merger structure.
- Development Uncertainty: No assurance that drug candidates (IT-101, CALAA-01) will succeed in clinical trials or receive FDA approval.
- Funding Requirements: Continued losses are expected before substantial revenue is generated; future funding may be required via equity, debt, or collaborations.
Investor Verification Checklist
- Cash Burn Rate: Verify the sufficiency of the $30.8 million in liquid assets to cover the projected operating losses through Q2 Fiscal 2008, considering the $7 million contingent commitment to Calando.
- CNI Merger Impact: Assess the commercial viability of the $5.4 million IPR&D charge and the timeline for Unidym to generate significant revenue from carbon nanotube products.
- Clinical Trial Progress: Monitor the status of Insert's Phase I trial results (expected late 2007) and Calando's IND filing (expected September 2007) as critical value drivers.
- Equity Dilution: Review the impact of recent private placements (May 2007) and outstanding options/warrants on future earnings per share.
- Revenue Quality: Distinguish between recurring product sales (Unidym) and non-recurring funded research/grant revenue.